|
Oct 7
|
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
|
|
Oct 7
|
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
|
|
Oct 7
|
AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history
|
|
Aug 8
|
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
|
|
Aug 7
|
Top Analyst Reports for AstraZeneca, TotalEnergies & ConocoPhillips
|
|
Aug 6
|
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
|
|
Aug 5
|
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?
|
|
Aug 5
|
Why monitoring workers with AI won't boost performance
|
|
Aug 4
|
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
|
|
Aug 2
|
Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
|
|
Aug 2
|
Here’s Why AstraZeneca PLC (AZN) Increased in Q2
|
|
Aug 2
|
Q2 2024 Ionis Pharmaceuticals Inc Earnings Call
|
|
Aug 1
|
Q2 2024 Paysign Inc Earnings Call
|
|
Jul 29
|
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
|
|
Jul 28
|
AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776
|
|
Jul 27
|
AstraZeneca Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Jul 26
|
FDA committee proposes overhaul of perioperative lung cancer trials
|
|
Jul 26
|
3 Surprisingly Underrated Stocks to Buy Right Now
|
|
Jul 26
|
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
|
|
Jul 26
|
Top 3 UK Stocks Estimated To Be Undervalued In July 2024
|